VP50.05: Histopathological placenta examination as a verification of pre‐eclampsia and fetal growth restriction symptoms

Abstract

Virtual poster abstracts screening for pre-eclampsia and the use of low dose aspirin (ASA) for the prevention of pre-eclampsia. Methods: A brief national-wide online survey was designed to assess the knowledge on pre-eclampsia screening and the usage of ASA for pre-eclampsia prevention. Descriptive statistics were used to characterize the participants' demographic characteristics. Chi-square tests were used to assess differences in health professionals' knowledge on PE screening and ASA usage for PE prevention between provider groups to identify key knowledge gaps. Results: 336 respondents completed the survey: 55.1% OB/GYN,17.0% FP, 14.6%, MFM, 10.0% MW. Guidelines followed: SOGC 57.2%, ACOG 17%, NICE 7.5%, local guidelines 18.2%. Percentage of respondents who prescribe ASA for prevention of pre-eclampsia; 96.7%, prior to 16 weeks' gestation: 96.6%, recommended dose162 mg OD: 38% MFMs 61.2%, OB/GYN 48.6%, FP 45.6%, and MW 38.2%), recommended time of day to take ASA: bedtime 56.5%, recommended gestational age to stop ASA: 36 weeks gestation MFMs (87.8%), Ob/Gyns (71.9%), MWs (67.6%) and FPs (59.6%, p = 0.014). Conclusions: This study provides important information regarding the current practice among obstetric care providers in Canada with regard to pre-eclampsia screening and prevention. While most recommend ASA for the prevention of pre-eclampsia, the screening guidelines followed, ASA dosage and dosage schedules recommended, and timing of stopping of ASA were variable. This baseline knowledge will enable the focused development of educational materials for implementation of PE screening and prevention based on recent high grade evidence regarding predictive screening algorithms and optimal use of ASA for prevention. VP50.05 Histopathological placenta examination as a verification of pre-eclampsia and fetal growth restriction symptoms